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Background: Many studies evaluated the best predictors for cardiovascular disease (CVD) events in individuals with
type 2 diabetes (T2D), but few studies examined the factors most strongly associated with mortality in T2D. The
Diabetes Heart Study (DHS), an intensively phenotyped family-based cohort enriched for T2D, provided an
opportunity to address this question.
Methods: Associations with mortality were examined in 1022 European Americans affected by T2D from 476 DHS families.
All-cause mortality was 31.2 % over an average 9.6 years of follow-up. Cox proportional hazards models with sandwich-
based variance estimation were used to evaluate associations between all-cause and CVD mortality and 24 demographic
and clinical factors, including coronary artery calcified plaque (CAC), carotid artery intima-media thickness, medications,
body mass index, waist hip ratio, lipids, blood pressure, kidney function, QT interval, educational attainment, and
glycemic control. Nominally significant factors (p < 0.25) from univariate analyses were included in model selection
(backward elimination, forward selection, and stepwise selection). Age and sex were included in all models.
Results: The all-cause mortality model selected from the full DHS sample included age, sex, CAC, urine albumin:
creatinine ratio (UACR), insulin use, current smoking, and educational attainment. The CVD mortality model selected
from the full sample included age, sex, CAC, UACR, triglycerides, and history of CVD events. Beyond age, the most
significant associations for both mortality models were CAC (2.03 × 10−4≤ p≤ 0.001) and UACR (1.99 × 10−8≤ p≤
2.23 × 10−8). To confirm the validity of the main predictors identified with model selection using the full sample, a
two-fold cross-validation approach was used, and similar results were observed.
Conclusions: This analysis highlights important demographic and clinical factors, notably CAC and albuminuria, which
predict mortality in the general population of patients with T2D.
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The Diabetes Heart Study (DHS) is an ongoing family-
based cohort study investigating the epidemiology and gene-
tics of cardiovascular disease (CVD) in a population-based
sample. Prior analyses in this type 2 diabetes (T2D)-enriched
cohort [1] have individually examined contributors to all-
cause and CVD mortality. Coronary artery calcified athero-
sclerotic plaque (CAC), a measure of subclinical CVD [2, 3],* Correspondence: dbowden@wakehealth.edu
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creativecommons.org/publicdomain/zero/1.0/C-reactive protein (CRP) [4], biventricular volume [5], heart
rate-corrected electrocardiographic QT interval [6], serum
albumin and creatine, estimated glomerular filtration rate
(eGFR), and urine albumin:creatinine ratio (UACR) [7] were
all found to predict mortality in the DHS.
Prior studies have examined risk prediction scores for
CVD events in patients with T2D [8, 9], which is an im-
portant contributor to mortality [10]. However, fewer
studies have attempted to evaluate the best predictors
of all-cause and CVD mortality in T2D [11–14]. We
performed a comprehensive analysis of which factors
were the strongest independent predictors of all-cause
and CVD mortality using model selection (backwardrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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in European Americans (EAs) with T2D from the DHS.
Methods
Study design and sample
The DHS recruited T2D-affected siblings without ad-
vanced renal insufficiency from 1998 through 2005 in
western North Carolina. T2D was defined as diabetes
developing after the age of 35 years initially treated with
changes in diet and exercise and/or oral agents, in the
absence of historical evidence of ketoacidosis or initial
treatment with insulin. Fasting glucose and glycated
hemoglobin (HbA1c) concentrations were assessed at the
exam visit. Ascertainment and recruitment criteria have
been described [1]. DHS participants were recruited
from the general population and broadly reflect the
demography of T2D in our community. Importantly,
prior evidence of CVD was not an exclusion to partici-
pate. All study protocols were approved by the Institu-
tional Review Board at Wake Forest School of Medicine,
and all participants provided written informed consent.
Participant examinations were conducted in the Gen-
eral Clinical Research Center of Wake Forest Baptist
Medical Center. Examinations included interviews for
medical history and health behaviors, anthropometric
measures, resting blood pressure, electrocardiography,
fasting blood sampling for laboratory analyses, and spot
urine collection. Low-density lipoprotein (LDL) choles-
terol was calculated using the Friedewald equation, and
LDL measures were considered valid for subjects whose
triglycerides were less than 400 mg/dL. Estimated glom-
erular filtration rate (eGFR) was computed using the
CKD-EPI equation [15]. CAC was assessed using com-
puted tomography (CT), summing the left main, left an-
terior descending, circumflex, posterior descending, and
right coronary arteries. CT scans were performed on
multi-detector CT scanners with cardiac gating in chest
scans. CAC scores were measured as previously de-
scribed and validated [16, 17]. Data on prior CVD events
was self-reported by participants and non-adjudicated.
Individuals were considered to have a history of prior
CVD if they self-reported prior MI, angina, stroke, or
vascular procedures including coronary angioplasty, cor-
onary artery bypass graft, or endarterectomy, or if they
had Q wave abnormalities indicative of prior MI.
Mortality was assessed using the National Social Se-
curity Death Index. For deceased participants, length of
follow-up was determined from the date of initial study
visit to date of death. For all other participants the
length of follow-up was determined from the date of the
initial study visit to December 31, 2013. When possible,
copies of death certificates were obtained from county
or state Vital Records Offices to determine cause of
death. Both all-cause and CVD mortality were analyzed;cause of death was categorized based on death certifi-
cates as CVD mortality (myocardial infarction, congest-
ive heart failure, cardiac arrhythmia, sudden cardiac
death, peripheral vascular disease, and stroke) or as mor-
tality from other causes. For 18 patients, cause of death
information could not be obtained, so these participants
were excluded from analyses of CVD mortality.
Statistical methods
Cox proportional hazards models with sandwich-based
variance estimation (due to the family structure of the
DHS) in SAS 9.3 were used to evaluate associations with
mortality. For model building, 24 potential predictors of
mortality for which data was available for most individ-
uals in the cohort, including CAC, carotid artery intima
media thickness (IMT), medications, body mass index
(BMI), waist hip ratio (WHR), lipids, blood pressure, kid-
ney function measures, electrocardiographic QT interval,
educational attainment, and glycemic control measures,
were evaluated in separate models for their association
with all-cause mortality and CVD mortality. Variables
were transformed prior to analysis; the square root of BMI
and high-density lipoprotein (HDL) cholesterol, the square
of WHR, and the natural log of glucose, HbA1c, CAC,
total cholesterol, triglycerides, UACR, QT interval, dia-
betes duration, IMT, and mean arterial pressure were
used. Nominally significant factors (p < 0.25) from univari-
ate analyses were included in model selection performed
in SAS 9.3. We confirmed that no factors included in
model selection were strongly correlated (r > 0.8). Age and
sex were included in all models. For backward elimination
selection, factors with a p-value < 0.05 for association with
mortality were retained in the model. For stepwise selec-
tion, factors meeting a threshold of a p-value < 0.25 could
enter into the model but required a p-value < 0.05 to be
retained. For forward selection, factors meeting a thresh-
old of a p-value < 0.05 could enter into the model. In our
analysis, results from the multiple Cox regression models
were concordant for forward, backward, and stepwise
model selections. Calculations for area under the receiver
operating characteristic curve (AUC) were performed in
STATA version 12.1.
Results
All self-described EAs from the DHS with T2D (1022 in-
dividuals from 476 families) were included in the ana-
lyses. Table 1 displays their demographic and clinical
characteristics, presented for the full sample and strati-
fied by mortality status. For the full cohort, mean ±
standard deviation (SD) diabetes duration was 10.4 ±
7.2 years. Prevalence of hypertension, obesity, subclinical
CVD based on CAC, and prior CVD events were high.
Over a mean ± SD follow-up of 9.6 ± 3.2 years, all-cause
mortality was 31.2 % and CVD mortality was 14.3 %.
Table 1 Demographic and clinical characteristics of European American participants with type 2 diabetes, stratified by mortality status
Full Sample (n = 1022) Living (n = 703) Deceased (n = 319)
Trait Mean (SD) or % Median (range) Mean (SD) or % Median (range) Mean (SD) or % Median (range)
Age (years) 62.43 (9.07) 62.80 (34.21, 85.98) 60.64 (8.48) 60.54 (34.21, 81.77) 66.36 (9.09) 67.03 (34.34, 85.98)
Female Sex (%) 51.5 % 54.8 % 44.2 %
Current Smoking (%) 16.1 % 14.0 % 20.8 %
Past Smoking (%) 43.4 % 43.6 % 43.1 %
History of Cardiovascular Disease (%) 43.2 % 37.3 % 56.1 %
All-Cause Mortality (%) 31.2 % 0 % 100 %
Cardiovascular Disease Mortality (%) 14.3 % 0 % 47.8 %
Educational Attainment- Less than High School (%) 25.6 % 20.8 % 36.4 %
Educational Attainment- High School (%) 49.2 % 51.4 % 44.1 %
Educational Attainment- Greater than High School (%) 25.2 % 27.8 % 19.5 %
Body Mass Index (kg/m2) 32.38 (6.58) 31.32 (17.10, 57.97) 32.67 (6.40) 31.61 (17.10, 57.97) 31.75 (6.93) 30.54 (17.54, 56.92)
Waist Hip Ratio 0.941 (0.082) 0.944 (0.436, 1.246) 0.937 (0.077) 0.939 (0.648, 1.234) 0.949 (0.091) 0.955 (0.436, 1.246)
Glucose (mg/dL) 147.9 (56.15) 135 (16, 463) 145.6 (51.17) 134 (16, 463) 152.9 (65.60) 140 (46, 436)
Glycated Hemoglobin (%) 7.60 (1.72) 7.20 (4.30, 18.30) 7.49 (1.61) 7.10 (4.60, 16.40) 7.84 (1.92) 7.60 (4.30, 18.30)
Diabetes Duration (years) 10.42 (7.15) 8 (0, 46) 9.32 (6.39) 7 (0, 46) 12.80 (8.09) 11 (1, 41)
Coronary Artery Calcified Plaque (mass score) 1856 (3335) 449.5 (0, 50415) 1328 (3038) 256.5 (0, 50415) 3048 (3657) 1632 (0, 22378)
Carotid Intima Media Thickness (mm) 0.683 (0.136) 0.659 (0.449, 1.569) 0.664 (0.127) 0.639 (0.449, 1.569) 0.723 (0.144) 0.700 (0.456, 1.316)
Total Cholesterol (mg/dL) 185.2 (43.42) 181 (65, 427) 184.5 (43.15) 180 (65, 427) 186.9 (44.04) 183 (70, 386)
HDL (mg/dL) 42.16 (11.89) 41 (8, 98) 42.46 (11.59) 41 (14, 94) 41.49 (12.52) 40 (8, 98)
Triglycerides (mg/dL) 208.9 (138.8) 176 (30, 1310) 206.0 (136.4) 173 (30, 1310) 215.3 (143.9) 183 (30, 1065)
LDL (mg/dL) 103.0 (32.6) 100 (12, 236) 102.2 (32.4) 100 (14, 207) 104.9 (33.1) 103 (12, 236)
Pulse Pressure (mmHg) 67.09 (16.93) 65.5 (28, 159) 65.53 (15.85) 64 (28, 124) 70.52 (18.67) 69.5 (31, 159)
Mean Arterial Pressure (mmHg) 95.05 (11.24) 94 (66.5, 154) 95.19 (10.33) 94 (66.5, 140.3) 94.75 (13.02) 93.17 (67.33, 154)
Estimated Glomerular Filtration Rate (ml/min/1.73 m2) 65.76 (18.38) 63.77 (8.91, 126.4) 67.95 (17.86) 65.43 (20.97, 122.2) 60.96 (18.62) 58.43 (8.91, 126.4)
Urine Albumin:creatinine Ratio (mg/g) 121.5 (530.5) 14.29 (0.48, 9449) 68.49 (390.8) 11.57 (0.48, 8878) 239.8 (741.5) 23.08 (0.78, 9449)
QT Interval (ms) 393.8 (33.14) 392.0 (270.1, 564.0) 393.2 (32.27) 392.0 (310.1, 564.0) 395.0 (34.93) 392.0 (270.1, 526.0)
High Blood Pressure Medications (%) 75.5 % 72.0 % 83.4 %
Statin Use (%) 42.7 % 44.8 % 37.9 %
Oral Hypoglycemic Medications (%) 78.8 % 79.0 % 78.4 %
Insulin Use (%) 27.3 % 22.9 % 37.0 %
C-reactive Protein (mg/dL) 0.611 (1.004) 0.296 (0.005, 12.73) 0.529 (0.793) 0.28 (0.005,9.573) 0.801 (1.355) 0.353 (0.008,12.73)
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factors with all-cause and CVD mortality in the full EA
T2D-affected cohort are shown in Table 2. Demographic
and clinical factors were selected for model selection
based on their associations with all-cause or CVD mortal-
ity (p < 0.25) (Table 2). Based on these univariate associa-
tions, model selection for all-cause mortality included
HbA1c, CAC, pulse pressure, HDL, eGFR, UACR, diabetes
duration, BMI, high blood pressure medication use, insu-
lin use, current smoking, history of CVD, educational at-
tainment (less than high school, high school, greater than
high school), WHR, mean arterial pressure, and IMT.
Model selection for CVD mortality included fasting glu-
cose, HbA1c, CAC, pulse pressure, HDL, triglycerides,
eGFR, UACR, QT interval, diabetes duration, BMI, high
blood pressure medication use, insulin use, history of
CVD, educational attainment, WHR, and IMT.Table 2 Associations of demographic and clinical factors with all-ca
All-cause Mortality
Trait HR 95 % HR CI
Age (years) 1.86 1.62 2.1
Female Sex (%) 0.68 0.54 0.8
Current Smoking (%) 1.44 1.11 1.8
Past Smoking (%) 0.99 0.79 1.2
History of Cardiovascular Disease (%) 1.91 1.52 2.4
Educational attainment (3 levels) 0.68 0.58 0.8
dy Mass Index (kg/m2) 0.87 0.77 0.9
Waist Hip Ratio 1.16 1.02 1.3
Glucose (mg/dL) 1.04 0.92 1.1
Glycated Hemoglobin (%) 1.09 0.97 1.2
Diabetes duration (years) 1.54 1.36 1.7
Coronary Artery Calcified Plaque (mass score) 2.01 1.7 2.3
Carotid Intima Media Thickness (mm) 1.38 1.25 1.5
Total Cholesterol (mg/dL) 1.01 0.91 1.1
HDL (mg/dL) 0.93 0.82 1.0
Triglycerides (mg/dL) 1.01 0.9 1.1
LDL (mg/dL) 1.05 0.94 1.1
Pulse Pressure (mmHg) 1.3 1.16 1.4
Mean Arterial Pressure (mmHg) 0.9 0.79 1.0
Estimated Glomerular Filtration Rate (ml/min/1.73 m2) 0.63 0.55 0.7
Urine Albumin:creatinine Ratio (mg/g) 1.56 1.42 1.7
QT Interval (ms) 1.02 0.91 1.1
High Blood Pressure Medications (%) 1.72 1.28 2.3
Statin Use (%) 0.88 0.7 1.1
Oral Hypoglycemic Medications (%) 1.04 0.79 1.3
Insulin Use (%) 1.71 1.35 2.1
Relationships assessed using univariate Cox proportional hazards models. Hazards ratio
variables) or change in group assignment (dichotomous variables). For medication use
medication class. CI, Confidence IntervalThe all-cause mortality model selected from the full
sample included age, sex, CAC, UACR, insulin use,
current smoking, and educational attainment (Table 3).
Other than age, the most significant associations with
all-cause mortality were for CAC (p = 2.03 × 10−4, hazard
ratio (HR) = 1.48 for a standard deviation (SD) change)
and UACR (p = 2.23 × 10−8, HR = 1.37 for a SD change).
The CVD mortality model selected from the full sample
included age, sex, CAC, UACR, triglycerides, and history
of CVD (Table 3). Similar to the all-cause mortality ana-
lysis, other than age, the most significant associations
with CVD mortality were for CAC (p = 0.001, HR = 1.71
for a SD change) and UACR (p = 1.99 × 10−8, HR = 1.51
for a SD change).
To confirm the validity of the most important predic-
tors identified with model selection using the full DHS
sample, a two-fold cross-validation approach was used,use and cardiovascular disease (CVD) mortality
CVD mortality
p-value n HR 95 % HR CI p-value n
3 <1 × 10−16 1022 1.74 1.41 2.13 1.40 × 10−7 1004
5 8.83 × 10−4 1022 0.58 0.41 0.82 0.002 1004
8 0.006 1018 1.04 0.66 1.63 0.866 1000
3 0.896 1018 1.13 0.82 1.57 0.452 1000
1 3.86 × 10−8 1013 3.25 2.25 4.69 3.21 × 10−10 995
1 1.73 × 10−5 1011 0.74 0.58 0.95 0.02 993
9 0.033 1022 0.89 0.74 1.07 0.225 1004
2 0.029 1012 1.2 1 1.45 0.049 994
7 0.512 1020 1.16 0.98 1.38 0.089 1002
2 0.169 1016 1.23 1.06 1.43 0.008 998
4 5.62 × 10−12 1005 1.7 1.41 2.04 2.22 × 10−8 987
7 1.11 × 10−16 968 2.47 1.91 3.21 8.48 × 10−12 952
3 5.20 × 10−10 928 1.42 1.24 1.63 7.32 × 10−7 911
3 0.796 1003 1 0.86 1.17 1 986
5 0.228 1003 0.87 0.72 1.04 0.133 986
4 0.841 1003 1.12 0.95 1.33 0.172 986
7 0.413 928 0.93 0.79 1.1 0.396 912
6 8.24 × 10−6 1019 1.35 1.13 1.61 7.71 × 10−4 1001
4 0.149 1019 0.95 0.76 1.2 0.685 1001
2 3.60 × 10−11 1021 0.63 0.51 0.78 2.75 × 10−5 1003
2 <1 × 10−16 1000 1.76 1.54 2.01 <1 × 10−16 982
6 0.709 985 1.13 0.93 1.38 0.212 968
2.63 × 10−4 1022 2.28 1.41 3.69 7.86 × 10−4 1004
1 0.293 1020 1.02 0.72 1.46 0.91 1002
8 0.769 1022 1.02 0.67 1.54 0.942 1004
7 8.51 × 10−6 1022 1.84 1.32 2.58 3.55 × 10−4 1004
s (HRs) are for a one standard deviation change in the predictor (continuous
HRs, the HRs are for risk of mortality among those individuals using the given
Table 3 Models selected for all-cause and cardiovascular disease (CVD) mortality in European Americans with type 2 diabetes
Trait Hazard Ratio 95 % Hazard Ratio Confidence Interval p-value
All-cause mortality
Age 1.72 1.46 2.02 6.46 × 10−11
Female Sex 0.93 0.71 1.21 0.565
Urine Albumin:creatinine Ratio 1.37 1.23 1.53 2.23 × 10−8
Coronary Artery Calcified Plaque 1.48 1.20 1.81 2.03 × 10−4
Current Smoking 1.79 1.30 2.46 3.38 × 10−4
Insulin Use 1.50 1.16 1.93 0.002
Educational Attainment 0.76 0.65 0.91 0.002
CVD mortality
Age 1.57 1.18 2.08 0.002
Female Sex 0.94 0.63 1.40 0.756
Urine Albumin:creatinine Ratio 1.51 1.31 1.74 1.99 × 10−8
Coronary Artery Calcified Plaque 1.71 1.23 2.38 0.001
Triglycerides 1.28 1.05 1.56 0.017
History of Cardiovascular Disease 1.59 1.03 2.46 0.036
Models were selected using backward elimination, forward selection, and stepwise selection. Age and sex were forced into all models. Hazards ratios (HRs) are for
a one standard deviation change in the predictor (continuous variables) or change in group assignment (dichotomous variables). For medication use HRs, the HRs
are for risk of mortality among those individuals using the given medication class
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roughly equal halves. The analysis for the full sample
was repeated separately in each random dataset. In each
random dataset, demographic and clinical factors were
selected to include in model building based on their uni-
variate associations with all-cause or CVD mortality
(Additional file 1). Models were selected using forward,
backward, and stepwise selections for all-cause and CVD
mortality in random datasets 1 and 2 (Additional files 2
and 3). As the associated predictors selected from each
dataset differed slightly, a combined model including
factors selected in the final model for each dataset was
created for both all-cause and CVD mortality. Therefore,
from this two-fold cross-validation approach, the all-
cause mortality model included age, sex, CAC, UACR,
diabetes duration, current smoking, educational attain-
ment, insulin use, and WHR, while the CVD mortality
model included age, sex, CAC, UACR, history of CVD
events, and diabetes duration. The factors selected are
similar to those observed using the full sample, which
shows that the results are stable with no evidence of
overfitting. This full model was fitted in both random
datasets, with a basic model limited to age and sex also
fitted as a comparison to the full model.
Predicted values were then derived in each randomly
selected dataset using regression coefficients derived
from fitting the model in the opposite dataset, allowing
calculation of average AUC for each dataset (Table 4),
both for the full model derived using the two-fold cross-
validation approach and a basic model including only age
and sex. The full model significantly improved predictionof both all-cause and CVD mortality (p < 0.05) in both
random datasets (Table 4). An estimate of AUC for the
whole EA cohort was also derived by fitting the models
derived using the two-fold cross-validation approach in
the whole sample, with an AUC of 0.788 for the full all-
cause mortality model in the whole sample, compared to
0.699 for a basic model containing only age and sex (p =
6.50 × 10−9 for improved prediction using the full model).
Similarly, the full CVD mortality model had an AUC of
0.764, compared to 0.652 for a basic model containing
only age and sex (p = 4.14 × 10−7 for improved prediction
using the full model) (Table 4).
Factors which were predictors of mortality in the DHS
in previous analyses, such as CRP [4] and biventricular
volume [5], were not included in the main model selection
due to lower sample size (n = 848 for CRP, n = 771 for
biventricular volume). When adding biventricular volume
to the full all-cause and CVD mortality models selected
using a two-fold cross-validation approach, biventricular
volume was nominally associated with increased all-cause
mortality risk (HR = 1.21 for a SD change, p = 0.053)
(Table 5) and more strongly associated with CVD mortal-
ity risk (HR = 1.52 for a SD change, p = 0.002) (Table 6). In
contrast, CRP was a significant predictor when added to
the all-cause mortality model (HR = 1.30 for a SD change,
p = 0.001) (Table 5), but not the CVD mortality model
(HR = 1.19 for a SD change, p = 0.167) (Table 6).
Discussion
This set of DHS analyses highlights demographic and
clinical factors independently predictive of mortality in
Table 4 Average area under the receiver operating characteristic curve (AUC) for the all-cause and cardiovascular disease (CVD)
mortality models
Data Outcome Model AUC 95 % Confidence Interval p-value
Random 1 All-cause mortality Basic 0.697 (0.644, 0.749) 0.011
All-cause mortality Full 0.759 (0.710, 0.807)
CVD mortality Basic 0.658 (0.590, 0.726) 0.002
CVD mortality Full 0.764 (0.705, 0.823)
Random 2 All-cause mortality Basic 0.693 (0.638, 0.747) 0.0001
All-cause mortality Full 0.777 (0.732, 0.823)
CVD mortality Basic 0.614 (0.534, 0.694) 0.0003
CVD mortality Full 0.725 (0.661, 0.789)
Full Cohort All-cause mortality Basic 0.699 (0.661, 0.737) 6.50 × 10−9
All-cause mortality Full 0.788 (0.756, 0.821)
CVD mortality Basic 0.652 (0.600, 0.704) 4.14 × 10−7
CVD mortality Full 0.764 (0.721, 0.807)
These models were derived using a two-fold cross-validation approach in each randomly selected dataset and in the full cohort. Basic models included age and
sex only. Full models for all-cause mortality included age, sex, coronary artery calcified plaque, urine albumin:creatinine ratio, diabetes duration, current smoking,
educational attainment, insulin use, and waist hip ratio. Full models for CVD mortality included age, sex, coronary artery calcified plaque, urine albumin:creatinine
ratio, history of CVD events, and diabetes duration. P-values for comparing the predictive power of the basic model with the full model are listed
Raffield et al. Diabetology & Metabolic Syndrome  (2015) 7:58 Page 6 of 11EAs with T2D. Most prior mortality model analyses in
individuals with T2D have included a more limited set of
clinical and demographic factors, for example BMI, lipids,
medications, glycemic control, and eGFR, compared to
those available in the DHS. As such, the literature does
not fully address which factors may predict all-cause and
CVD mortality by considering novel predictors, particu-
larly CAC, in individuals with T2D. All the clinical and
demographic factors included in model selection can be
hypothesized to contribute to mortality. Our analysis
shows, out of many mortality associated predictors, which
ones are the most important to consider in T2D-affected
individuals using a statistical model selection approach.
While results from model selection for all-cause and CVD
mortality differed slightly between model selection using
the full cohort and model selection using a two-fold cross-
validation approach, the key factors selected, notably CAC
and UACR, did not differ. This demonstrates the validity
of model selection results. Other factors selected using the
full sample, such as current smoking, insulin use, and edu-
cational attainment with all-cause mortality and history of
cardiovascular disease with CVD mortality, were also in-
cluded in the models selected using a two-fold cross-
validation approach. This indicates results from the model
selection are stable and reveals important factors to con-
sider in future analyses of mortality in community-based
cohorts of T2D-affected individuals.
The two factors most consistently associated with all-
cause and CVD mortality were CAC and albuminuria.
Prior studies in T2D have demonstrated striking associa-
tions of UACR with renal end-points, CVD events, CVD
mortality, and all-cause mortality [18–20]. Prior mortal-
ity analyses with shorter follow-up in the full DHScohort with and without T2D (83.7 % T2D-affected) also
found UACR to be associated with all-cause and CVD
mortality, independent from CAC and other CVD risk
factors such as age, sex, T2D affection status, BMI, current
smoking, hypertension, dyslipidemia, renin-angiotensin
system blocking medications, and prior CVD [7]. As in
prior analyses of individuals with T2D [19], UACR was a
stronger predictor of CVD mortality than eGFR in our
models. UACR is a marker of generalized endothelial dys-
function, more so than kidney disease specifically, which is
better reflected by changes in eGFR. UACR was not
assessed in some analyses building mortality prediction
models in T2D [11, 12], but it was selected as a significant
predictor of elevated all-cause mortality in the Hong Kong
Diabetes Registry cohort [13] and the Gargano Mortality
Study [14]. The incorporation of CAC significantly im-
proves mortality risk prediction, which is expected. CAC
is a strong independent predictor of CVD events and mor-
tality in the general population and in T2D [2, 3, 21–27],
with individuals affected by diabetes tending to have
higher CAC [28]. Recent model building using partici-
pants with T2D from the Multi-Ethnic Study of Athero-
sclerosis (MESA) and the Heinz Nixdorf Recall Study
found that using CAC improved risk prediction for inci-
dent CVD events, an important contributor to mortality
risk in those with T2D, above the Framingham or United
Kingdom Prospective Diabetes study risk models which
include more conventional risk factors such as age, sex,
systolic blood pressure, HbA1c, and lipid levels [9]. Not-
ably, carotid IMT, another novel predictor of CVD risk in
T2D, was not selected for in these CVD event prediction
models in T2D [9], consistent with our finding that IMT
was not an independent predictor of mortality in the DHS
Table 5 Addition of C-reactive protein and biventricular volume to model selected for all-cause mortality





p-value Trait Hazard Ratio 95 % Hazard Ratio
Confidence Interval






Age 1.67 1.42 1.96 3.68 × 10−10 Age 1.80 1.52 2.13 6.54 × 10−12 Age 1.81 1.53 2.15 9.65 × 10−12
Female Sex 0.92 0.70 1.22 0.581 Female Sex 0.86 0.62 1.19 0.356 Female Sex 1.24 0.85 1.81 0.269
Coronary Artery
Calcified Plaque
1.50 1.24 1.81 3.32 × 10−5 Coronary Artery
Calcified Plaque
1.44 1.17 1.77 0.001 Coronary Artery
Calcified Plaque
1.45 1.15 1.82 0.001
Urine Albumin:
creatinine Ratio
1.35 1.21 1.51 1.10 × 10−7 Urine Albumin:
creatinine Ratio
1.35 1.20 1.52 7.85 × 10−7 Urine Albumin:
creatinine Ratio
1.32 1.17 1.49 8.08 × 10−6
Diabetes
Duration
1.10 0.96 1.26 0.173 Diabetes Duration 1.05 0.91 1.21 0.505 Diabetes Duration 1.09 0.94 1.25 0.261
Current Smoking 1.70 1.25 2.31 7.38 × 10−4 Current Smoking 1.63 1.16 2.28 0.005 Current Smoking 2.00 1.42 2.83 8.46 × 10−5
Educational
Attainment
0.79 0.67 0.93 0.004 Educational
Attainment
0.79 0.66 0.94 0.010 Educational Attainment 0.78 0.65 0.94 0.008
Insulin Use 1.40 1.07 1.84 0.015 Insulin Use 1.49 1.11 2.00 0.008 Insulin Use 1.39 1.03 1.86 0.029
Waist Hip Ratio 1.01 0.86 1.19 0.913 Waist Hip Ratio 0.97 0.81 1.17 0.765 Waist Hip Ratio 1.01 0.86 1.20 0.868
C-reactive Protein 1.30 1.11 1.52 0.001 Biventricular Volume 1.21 1.00 1.48 0.053
The all-cause mortality model was selected using a two-fold cross-validation approach in European American participants with type 2 diabetes. Hazards ratios (HRs) are for a one standard deviation change in the predictor















Table 6 Addition of C-reactive protein and biventricular volume to model selected for cardiovascular disease mortality









p-value Trait Hazard Ratio 95 % Hazard Ratio
Confidence Interval
p-value
Age 1.36 1.08 1.73 0.010 Age 1.63 1.27 2.10 1.20 × 10−4 Age 1.75 1.36 2.27 1.66 × 10−5
Female Sex 0.98 0.68 1.42 0.929 Female Sex 1.02 0.67 1.55 0.942 Female Sex 1.52 0.90 2.55 0.116
Coronary Artery
Calcified Plaque
1.67 1.24 2.26 7.18 × 10−4 Coronary Artery
Calcified Plaque
1.60 1.15 2.23 0.005 Coronary Artery
Calcified Plaque
1.40 0.98 2.00 0.067
Urine Albumin:
creatinine Ratio
1.52 1.32 1.75 7.59 × 10−9 Urine Albumin:
creatinine Ratio
1.57 1.35 1.83 7.31 × 10−9 Urine Albumin:
creatinine Ratio




1.69 1.11 2.57 0.014 History of
Cardiovascular
Disease
1.52 0.95 2.43 0.084 History of
Cardiovascular
Disease
1.55 0.98 2.45 0.063
Diabetes Duration 1.20 0.98 1.46 0.082 Diabetes Duration 1.04 0.84 1.28 0.736 Diabetes Duration 1.09 0.88 1.36 0.435
C-reactive Protein 1.19 0.93 1.51 0.167 Biventricular Volume 1.52 1.16 1.98 0.002
The cardiovascular disease mortality model was selected using a two-fold cross-validation approach in European Americans with type 2 diabetes. Hazards ratios (HRs) are for a one standard deviation change in the
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perior risk prediction and reclassification compared to ca-
rotid IMT [29, 30].
Demographic factors including current smoking, insu-
lin use, and educational attainment were also associated
with all-cause mortality in the DHS. Current smoking
[11, 12] and use of insulin [11–14] have been previously
included in prediction models as associated with ele-
vated mortality risk in analyses of individuals with T2D.
Lower educational attainment has also been associated
with elevated mortality risk in prior assessments of T2D,
although this was not always included in final selected
models, potentially due to the inclusion of correlated
variables such as income that were not used in our ana-
lysis [12]. History of CVD events being associated with
CVD mortality is not surprising, given the elevated risk
of secondary CVD events in those with established
CVD. History of CVD is strongly associated with CAC
burden (p < 1 × 10−16) but is still an independent pre-
dictor of CVD, but not all-cause, mortality.
Additional factors not included in the primary model
building analysis due to reduced sample size may also be
important to mortality risk prediction in T2D. Previous
analysis in the DHS with shorter mortality follow-up
time suggested that biventricular volume significantly in-
creased AUC for prediction of all-cause and CVD mor-
tality versus a model including age, sex, and CAC alone
[5]. This is substantiated by data from this analysis, with
biventricular volume improving prediction of CVD mor-
tality (Table 6). Biventricular volume can be derived
from the same CT scans used to evaluate CAC, but it
appears to be predictive of CVD mortality independent
of CAC burden, so this may be an important factor to
include in future analyses of mortality in T2D. CRP may
also need to be considered in future analyses. In a previ-
ously published analysis from the DHS, each one unit in-
crease in log transformed CRP was associated with a
1.5-fold increase in risk for all-cause mortality (HR 1.54;
95 % CI 1.33–1.77) [4]. Similar results were observed,
though with a slightly attenuated HR, when CRP was
added to our full all-cause mortality model from this
analysis (Table 5). The lack of association with CVD
mortality for CRP may not be surprising, as some stud-
ies have cast doubt on the causal role of CRP in CVD
events [31].
Recent work in the DHS highlighted demographic and
clinical factors associated with mortality in individuals
with T2D at very high CVD risk based on a CAC score
>1000, with, for example, higher HbA1c, longer diabetes
duration, reduced kidney function, reduced use of sta-
tins, and higher CRP associated with higher mortality
[32]. We attempted to perform model selection in only
T2D affected individuals with CAC >1000 using similar
methods to the analysis in the full T2D-affected DHSsample (data not shown). Models were not perfectly
concordant between forward, backward, and stepwise se-
lection, not surprisingly given the reduced sample size
(n = 371), but selected models all included CAC, UACR,
and HbA1c as contributors to elevated risk of all-cause
and CVD mortality in this very high risk sample, similar
to the results in the full T2D-affected cohort with the
exception of HbA1c, which was not selected in the full
T2D-affected cohort but appears to be a more important
predictor in the CAC > 1000 subgroup.
Limitations of the current analysis include the lack of
a replication cohort with similar mortality data and
demographic and clinical factors assessed, necessitating
use of a two-fold cross-validation approach. There are,
however, few studies with the same breadth of data in a
population-based sample of individuals with T2D. The
latter, we believe, is an important feature of the DHS
since it likely reflects what actually influences mortality
in the community, as opposed to in a clinical trial. Previ-
ous analyses have been performed in cohorts with differ-
ent recruitment strategies than the DHS, for example
population-based cohorts in Hong Kong [13] and Italy
[14], or cohorts extracted from electronic medical record
data whose diabetes was not as well characterized as the
DHS and with exclusions based on medication use [11].
None of these cohorts had data on all the novel mea-
sures of CVD risk available in the DHS. Length of
follow-up, over 9 years on average, was also greater than
in previous analyses [11–14], as was duration of T2D in
study participants [13, 14]. This long follow-up does
mean that some clinical guidelines and practices, for ex-
ample recommendations for statin use in all individuals
age 40–75 affected by diabetes [33], have changed since
the DHS was initiated and may influence future mortal-
ity risk. Data for some demographic and clinical factors
which predicted all-cause mortality in prior analyses in
T2D, such as cancer [13] or Charlson index, a measure
of comorbidity burden [12], were not available in the
DHS, while some factors available in the DHS, notably
CAC, were not used in prior model selection, making
direct comparisons of mortality models derived in T2D-
affected individuals difficult.
Additional analytic limitations include the relatively
small number of events, in particular for CVD mortality
(14.3 % of the cohort), which necessitated use of only
two-fold cross validation, as opposed to an analysis strat-
egy splitting the cohort by family into a greater number
of small random samples. Further validation of our risk
prediction models in additional cohorts of T2D-affected
patients would be necessary prior to clinical applications.
While these results highlight factors that may be import-
ant for mortality risk assessment in the T2D-affected
population, causal relationships are uncertain. The current
analyses were limited to individuals of EA descent, since
Raffield et al. Diabetology & Metabolic Syndrome  (2015) 7:58 Page 10 of 11levels of CAC differ from those in African Americans; dif-
ferent factors may impact mortality risk in other ethnic
groups.
Conclusions
The present results demonstrate the importance of
assessing UACR and CAC in particular for prediction of
CVD and all-cause mortality. Not all patients with T2D
are at equal risk of poor health outcomes and mortality,
and more comprehensive assessment in research and
clinical settings of these predictors of mortality, particu-
larly CAC, in T2D-affected individuals is needed.
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